Company intelligence / Profile preview
KeyBioscience AG
Lugano, Ticino, Switzerlandkeybioscience.com ↗
- Ownership
- Private
- Development stage
- Phase 2
01
Overview
KeyBioscience has developed several DACRA molecules with KBP-336 being their newest focus as a once-weekly injectable for metabolic osteoarthritis. A new molecule is anticipated to enter Phase 2 studies for obesity and osteoarthritis in late 2024, with plans to enroll 600 people and dual primary endpoints on body weight and alleviation of OA pain. Previous Phase 2 trials have shown significant weight loss in people with obesity and clinically meaningful improvement of glycaemic control.
- Therapeutic areas
- EndocrinologyRheumatology
- Modalities
- Synthetic peptidesDual Amylin Calcitonin Receptor Agonists (DACRAs)
- Industry
- Biotech
02
Drug pipeline
4 assets3 more assets in the full pipeline.
03
Partnerships
Eli Lilly and Company
Beyond the preview
Go deeper on KeyBioscience AG.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on KeyBioscience AG.